Activity of rIL-2, L19-IL2, and rituximab, alone and in combination, against localized lymphoma xenografts
| Treatment . | PR . | CR . | Relapse after CR . |
|---|---|---|---|
| Ramos | |||
| Saline | 0/9 | 0/9 | — |
| 6.6 μg rIL-2 | 0/4 | 0/4 | — |
| 20 μg L19-IL2 | 0/4 | 0/4 | — |
| 200 μg rituximab | 0/4 | 0/4 | — |
| 200 μg rituximab + 2.2 μg rIL-2 | 0/5 | 0/5 | — |
| 200 μg rituximab + 6.6 μg rIL-2 | 0/5 | 0/5 | — |
| 200 μg rituximab + 6.6 μg L19-IL2 | 1/5 | 4/5 | 4/4 |
| 200 μg rituximab + 20 μg L19-IL2 | 1/5 | 4/5 | 0/4 |
| DoHH-2 | |||
| Saline | 0/5 | 0/5 | — |
| 6.6 μg rIL-2 (+ SIP [L19]) | 0/5 | 0/5 | — |
| 20 μg L19-IL2 | 0/5 | 0/5 | — |
| 200 μg rituximab | 2/5 | 2/5 | 2/2 |
| 200 μg rituximab + 6.6 μg rIL-2 (+ SIP[L19]) | 3/5 | 2/5 | 1/2 |
| 200 μg rituximab + 20 μg L19-IL2 | 0/5 | 5/5 | 0/5 |
| Treatment . | PR . | CR . | Relapse after CR . |
|---|---|---|---|
| Ramos | |||
| Saline | 0/9 | 0/9 | — |
| 6.6 μg rIL-2 | 0/4 | 0/4 | — |
| 20 μg L19-IL2 | 0/4 | 0/4 | — |
| 200 μg rituximab | 0/4 | 0/4 | — |
| 200 μg rituximab + 2.2 μg rIL-2 | 0/5 | 0/5 | — |
| 200 μg rituximab + 6.6 μg rIL-2 | 0/5 | 0/5 | — |
| 200 μg rituximab + 6.6 μg L19-IL2 | 1/5 | 4/5 | 4/4 |
| 200 μg rituximab + 20 μg L19-IL2 | 1/5 | 4/5 | 0/4 |
| DoHH-2 | |||
| Saline | 0/5 | 0/5 | — |
| 6.6 μg rIL-2 (+ SIP [L19]) | 0/5 | 0/5 | — |
| 20 μg L19-IL2 | 0/5 | 0/5 | — |
| 200 μg rituximab | 2/5 | 2/5 | 2/2 |
| 200 μg rituximab + 6.6 μg rIL-2 (+ SIP[L19]) | 3/5 | 2/5 | 1/2 |
| 200 μg rituximab + 20 μg L19-IL2 | 0/5 | 5/5 | 0/5 |
SCID mice bearing established subcutaneous Ramos or DoHH-2 lymphoma xenografts were treated with the indicated therapeutic regimens. Responses were defined as partial remission (PR; at least 50% reduction of tumor volume) or complete remission (CR; no visible or palpable tumor). Data indicate number responding/total number of treatment group.
— indicates not applicable.